DE3372965D1 - Amide derivatives - Google Patents

Amide derivatives

Info

Publication number
DE3372965D1
DE3372965D1 DE8383303998T DE3372965T DE3372965D1 DE 3372965 D1 DE3372965 D1 DE 3372965D1 DE 8383303998 T DE8383303998 T DE 8383303998T DE 3372965 T DE3372965 T DE 3372965T DE 3372965 D1 DE3372965 D1 DE 3372965D1
Authority
DE
Germany
Prior art keywords
different
same
alkyl
hydrogen
acylanilides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8383303998T
Other languages
German (de)
English (en)
Inventor
Howard Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10531878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3372965(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Application granted granted Critical
Publication of DE3372965D1 publication Critical patent/DE3372965D1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE8383303998T 1982-07-23 1983-07-08 Amide derivatives Expired DE3372965D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8221421 1982-07-23

Publications (1)

Publication Number Publication Date
DE3372965D1 true DE3372965D1 (en) 1987-09-17

Family

ID=10531878

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8383303998T Expired DE3372965D1 (en) 1982-07-23 1983-07-08 Amide derivatives

Country Status (23)

Country Link
US (1) US4636505A (enExample)
EP (1) EP0100172B1 (enExample)
JP (2) JPS5933250A (enExample)
AT (1) ATE28864T1 (enExample)
AU (1) AU556328B2 (enExample)
CA (1) CA1249823A (enExample)
CS (1) CS399991A3 (enExample)
DE (1) DE3372965D1 (enExample)
DK (1) DK322783D0 (enExample)
ES (4) ES524392A0 (enExample)
FI (1) FI83770C (enExample)
GR (1) GR79232B (enExample)
HK (1) HK92690A (enExample)
HU (1) HU191296B (enExample)
IE (1) IE55941B1 (enExample)
IL (1) IL69217A (enExample)
LU (1) LU88769I2 (enExample)
MX (1) MX9203451A (enExample)
NL (1) NL950029I2 (enExample)
NO (2) NO164974C (enExample)
NZ (1) NZ204995A (enExample)
PT (1) PT77087B (enExample)
ZA (1) ZA835182B (enExample)

Families Citing this family (311)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54115075A (en) * 1978-02-28 1979-09-07 Cho Lsi Gijutsu Kenkyu Kumiai Plasma etching method
FR2540495B1 (fr) * 1983-02-07 1986-02-14 Roussel Uclaf Nouveaux derives de o-mercaptopropanamide et de ses homologues, leur procede de preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
GB8617652D0 (en) * 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
US4921941A (en) * 1987-07-01 1990-05-01 Schering Corporation Orally active antiandrogens
US4970303A (en) * 1988-02-03 1990-11-13 Xoma Corporation Linking agents and methods
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
GB9214120D0 (en) * 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
GB9305295D0 (en) * 1993-03-15 1993-05-05 Zeneca Ltd Therapeutic compounds
GB9310095D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
WO1995019770A1 (en) * 1994-01-21 1995-07-27 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
DE4420777A1 (de) 1994-06-15 1995-12-21 Bayer Ag Verfahren zur Herstellung von 4-Fluorthiophenol
AU696788B2 (en) * 1994-06-27 1998-09-17 Neutron Therapies Inc. Boron-containing hormone analogs and methods of their use in imaging or killing cells having hormone receptors
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US20090264534A1 (en) * 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
US6492554B2 (en) 2000-08-24 2002-12-10 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US20050038110A1 (en) * 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
US7518013B2 (en) 2000-08-24 2009-04-14 University Of Tennessee Research Foundation Selective androgen receptor modulators
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US7205437B2 (en) * 1996-11-27 2007-04-17 University Of Tennessee Research Foundation Selective androgen receptor modulators
AU7604798A (en) * 1997-05-30 1998-12-30 University Of Tennessee Research Corporation, The Non-steroidal agonist compounds and their use in male hormone therapy
WO1998055153A1 (en) * 1997-06-04 1998-12-10 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
DE19746512A1 (de) 1997-10-22 1999-04-29 Bayer Ag Verfahren zur Herstellung von Arylmercaptanen durch Hydrierung von Diaryldisulfiden
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
EP1107943A4 (en) * 1998-08-28 2002-07-24 Smithkline Beecham Corp PROCESS FOR THE PREPARATION OF 2-AMINO-5-CYANOPHENOL
US6472415B1 (en) * 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6184249B1 (en) 1998-12-18 2001-02-06 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
HU223950B1 (hu) * 1999-06-10 2005-03-29 Richter Gedeon Vegyészeti Gyár Rt. Eljárás a racém, valamint az R-(-)- és S-(+)-N-[4-ciano-3-(trifluor-metil)-fenil]-3-[(4-fluor-fenil)-szulfonil]-2-hidroxi-2-metil-propánsavamid előállítására
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1214295B1 (en) 1999-09-04 2006-11-02 AstraZeneca AB Hydroxyacetamidobenzenesulphonamide derivatives
DE60009319T2 (de) 1999-09-04 2005-03-31 Astrazeneca Ab Substituierte n-phenyl-2-hydroxy-2-methyl-3,3,3-trifluorpropanamid-derivative zur erhöhung der pyruvatdehydrogenaseaktivität
ES2307528T3 (es) 1999-09-04 2008-12-01 Astrazeneca Ab Amidas como inhibidores para la piruvato deshidrogenasa.
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
AU1968601A (en) * 1999-10-19 2001-04-30 Nobex Corporation Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof
EP1224167A1 (en) * 1999-10-27 2002-07-24 Nobex Corporation Resolution of intermediates in the synthesis of substantially pure bicalutamide
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia
GB0012293D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6828458B2 (en) 2000-05-25 2004-12-07 Biophysica, Inc. Topical antiandrogen for hair loss and other hyperandrogenic conditions
GB0016426D0 (en) * 2000-07-05 2000-08-23 Astrazeneca Ab Pharmaceutical combination
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US20030232792A1 (en) * 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US20070173546A1 (en) * 2000-08-24 2007-07-26 Dalton James T Selective androgen receptor modulators and method of use thereof
US8008348B2 (en) 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
DE60124322T2 (de) * 2000-08-24 2007-05-31 University Of Tennessee Research Foundation, Knoxville Selektive modulatoren des androgenrezeptors und methoden zu deren verwendung
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
WO2002024638A1 (en) 2000-09-21 2002-03-28 Bristol-Myers Squibb Company Process for the preparation of n-(substituted phenyl)-3-alkyl-, aryl- and heteroarylsulfonyl-2-hydroxy-2-alkyl- and haloalkylpropanamide compounds
LT2269604T (lt) 2001-02-19 2016-11-10 Novartis Ag Inkstų solidinių navikų gydymas rapamicino dariniu
EP1368001B1 (en) * 2001-02-27 2005-10-26 AstraZeneca AB Pharmaceutical formulation comprising bicalutamide
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
MXPA03010401A (es) 2001-05-16 2004-03-09 Novartis Ag Combinacion que comprende n-[5-[4- (4-metil- piperazino-metil) -benzoilamido] -2-metilfenil] -4-(3-piridil)-2 -pirimidin-amina, y un agente quimioterapeutico.
EP1406855A4 (en) * 2001-06-13 2006-04-19 Teva Gyogyszergyar Reszvenytar NOVEL PROCESS FOR THE PREPARATION OF RAC-BICALUTAMIDE AND INTERMEDIATE PRODUCTS THEREOF
US7102026B2 (en) * 2001-06-13 2006-09-05 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Process for preparing and isolating rac-bicalutamide and its intermediates
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
US7015253B2 (en) * 2001-07-10 2006-03-21 American Medical Systems, Inc. Regimen for treating prostate tissue and surgical kit for use in the regimen
US20060004042A1 (en) * 2001-08-23 2006-01-05 Dalton James T Formulations comprising selective androgen receptor modulators
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
AT410545B (de) * 2001-11-07 2003-05-26 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von chiralen alpha-hydroxycarbonsäuren
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
HRP20040588A2 (en) * 2001-12-06 2004-10-31 Gtx Inc Treating muscle wasting with selective androgen receptor modulators
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
AU2002354475B2 (en) * 2001-12-13 2008-08-14 Sumitomo Chemical Company, Limited Crystals of bicalutamide and process for their production
CN1646115B (zh) 2002-02-07 2010-06-09 Gtx公司 Sarms在制备用于治疗良性前列腺增生的药物中的应用
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
CN1639110A (zh) * 2002-02-28 2005-07-13 田纳西大学研究基金会 卤代乙酰胺和叠氮化物取代的化合物及其使用方法
US7344700B2 (en) 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
US7803970B2 (en) 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
EP1487458B1 (en) * 2002-02-28 2011-11-16 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
MXPA04011384A (es) 2002-05-16 2005-02-14 Novartis Ag Uso de agentes de union del receptor edg en cancer.
CN100537520C (zh) 2002-06-17 2009-09-09 田纳西大学研究基金会 N-桥连选择性雄激素受体调节剂及其使用方法
US7741371B2 (en) 2002-06-17 2010-06-22 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7297698B2 (en) 2002-07-12 2007-11-20 Astellas Pharma Inc. N-phenyl-(2R,5S) dimethylpiperazine derivative
US20040063782A1 (en) * 2002-09-27 2004-04-01 Westheim Raymond J.H. Bicalutamide forms
US6818766B2 (en) 2002-10-02 2004-11-16 Synthon Bv Process for making bicalutamide and intermediates thereof
JP2006506369A (ja) 2002-10-15 2006-02-23 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション メチレン架橋選択的アンドロゲン受容体調節剤及びその使用方法
US20040197928A1 (en) * 2002-10-15 2004-10-07 Dalton James T. Method for detecting selective androgen receptor modulators
CA2501867A1 (en) * 2002-10-15 2004-04-29 James T. Dalton Heterocyclic selective androgen receptor modulators and methods of use thereof
JP2006505563A (ja) * 2002-10-15 2006-02-16 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体調節剤による肥満治療
JP2006505564A (ja) * 2002-10-16 2006-02-16 ジーティーエックス・インコーポレイテッド Ｓａｒｍによる高齢男性のアンドロゲン減少に関連する病気の治療
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
US20040087810A1 (en) * 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
PL201541B1 (pl) * 2002-10-30 2009-04-30 Inst Farmaceutyczny Sposób wytwarzania N-(4-cyjano-3-trifluorometylofenylo)-2,3-epoksy-2-metylopropanamidu
PL201540B1 (pl) * 2002-10-30 2009-04-30 Inst Farmaceutyczny Sposób wytwarzania wysokiej czystości N-(4-cyjano-3-trifluorometylofenylo)-3-(4-fluorofenylosulfonylo)-2-hydroksy-2-metylopropanamidu
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
AU2004204800B8 (en) 2003-01-13 2011-05-26 University Of Tennessee Research Foundation Large-scale synthesis of selective androgen receptor modulators
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
AU2003209667A1 (en) * 2003-02-21 2004-09-09 Hetero Drugs Limited Bicalutamide polymorphs
US20040167103A1 (en) * 2003-02-24 2004-08-26 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
EP1596857B1 (en) 2003-02-27 2008-10-29 Wisconsin Alumni Research Foundation Pmcol for the treatment of prostate cancer
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
EP1558570A1 (en) * 2003-06-25 2005-08-03 Teva Gyogyszergyar Reszvenytarsasag Process for purifying and isolating rac-bicalutamide
DE602004026583D1 (de) * 2003-06-27 2010-05-27 Orion Corp Als androgenrezeptormodulatoren geeignete propionamidderivate
CN100462353C (zh) * 2003-06-27 2009-02-18 奥赖恩公司 用作雄激素受体调节剂的丙酰胺衍生物
FI20030958A0 (fi) * 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
WO2005012256A1 (en) 2003-07-22 2005-02-10 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
JP2005060302A (ja) * 2003-08-12 2005-03-10 Sumitomo Chemical Co Ltd Ｎ−メタクリロイル−４−シアノ−３−トリフルオロメチルアニリンの製造方法および安定化方法
US7816372B2 (en) * 2003-08-22 2010-10-19 Ligand Pharmaceuticals Incorporated 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
EP1673376A4 (en) * 2003-10-14 2010-06-23 Gtx Inc TREATMENT OF BONE DISEASES WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS
TW200523235A (en) * 2003-10-15 2005-07-16 Gtx Inc Anti-cancer compounds and methods of use thereof
JP2007512359A (ja) 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
AU2004305061A1 (en) 2003-12-16 2005-07-07 Gtx, Inc. Prodrugs of selective androgen receptor modulators and methods of use thereof
WO2005060951A2 (en) * 2003-12-19 2005-07-07 Bionaut Pharmaceuticals, Inc. Anti-neoplastic agents, combination therapies and related methods
JP3997255B2 (ja) 2004-02-13 2007-10-24 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンレセプターモジュレーター
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
SG152225A1 (en) 2004-04-07 2009-05-29 Novartis Ag Inhibitors of iap
WO2005100305A1 (en) 2004-04-13 2005-10-27 Warner-Lambert Company Llc Androgen modulators
WO2005102990A1 (en) 2004-04-22 2005-11-03 Warner-Lambert Company Llc Androgen modulators
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
ATE552235T1 (de) * 2004-06-07 2012-04-15 Univ Tennessee Res Foundation Selektive androgen-rezeptor-modulator und anwendungsverfahren dafür
ITMI20041222A1 (it) * 2004-06-17 2004-09-17 Cosma S P A Procedimento perfezionato per la sintesi di bicalutamide
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
BRPI0513020A (pt) 2004-07-08 2008-04-22 Warner Lambert Co moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação
BRPI0513301A (pt) 2004-07-14 2008-05-06 Sumitomo Chemical Co método para cristalização de bicalutamida
US20060258628A1 (en) * 2004-07-20 2006-11-16 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof
EP1789090A2 (en) * 2004-09-02 2007-05-30 Bionaut Pharmaceuticals, Inc. Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors
US20070105790A1 (en) * 2004-09-02 2007-05-10 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
US20080027010A1 (en) * 2004-09-02 2008-01-31 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using Na+/K+-ATPase inhibitors
WO2006028969A1 (en) * 2004-09-02 2006-03-16 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using na+/k+ atpase inhibitors
US20060135468A1 (en) * 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using NA+/K+ ATPase inhibitors
US20060135443A1 (en) * 2004-10-18 2006-06-22 Bionaut Pharmaceuticals, Inc. Use of Na*/K*-ATPase inhibitors and antagonists thereof
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
RU2436575C2 (ru) * 2005-01-21 2011-12-20 Астекс Терапьютикс Лимитед Соединения для использования в фармацевтике
ES2552338T3 (es) 2005-01-21 2015-11-27 Astex Therapeutics Limited Compuestos farmacéuticos
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US20080177109A1 (en) * 2005-03-29 2008-07-24 Usv Limited Novel Process for Preparation of Bicalutamide
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
CN101137655A (zh) 2005-06-17 2008-03-05 配体药物公司 雄激素受体调节剂化合物和方法
CA2513356A1 (en) * 2005-07-26 2007-01-26 Apotex Pharmachem Inc. Process for production of bicalutamide
JP2009510073A (ja) 2005-09-27 2009-03-12 ノバルティス アクチエンゲゼルシャフト カルボキシアミン化合物およびその使用方法
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US9006224B2 (en) 2005-11-21 2015-04-14 Novartis Ag Neuroendocrine tumor treatment
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
AU2006329551A1 (en) * 2005-12-27 2007-07-05 Dabur Pharma Limited An improved process for preparation of Bicalutamide
CA2642598C (en) * 2006-03-03 2014-05-27 Orion Corporation Selective androgen receptor modulators
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
EP3020706A1 (en) 2006-03-29 2016-05-18 The Regents Of The University Of California Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder
WO2007115289A2 (en) 2006-04-05 2007-10-11 Novartis Ag Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
RU2447891C2 (ru) 2006-04-05 2012-04-20 Новартис Аг Комбинации терапевтических средств, предназначенные для лечения рака
EP2026800A1 (en) 2006-05-09 2009-02-25 Novartis AG Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
WO2008013791A2 (en) * 2006-07-24 2008-01-31 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
CN107007581A (zh) 2006-08-24 2017-08-04 田纳西大学研究基金会 取代的n‑酰基苯胺及其使用方法
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
WO2008044033A1 (en) * 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US12290277B2 (en) 2007-01-02 2025-05-06 Aquabeam, Llc Tissue resection with pressure sensing
US9232959B2 (en) 2007-01-02 2016-01-12 Aquabeam, Llc Multi fluid tissue resection methods and devices
ES3034889T3 (en) 2007-01-02 2025-08-26 Aquabeam Llc Minimally invasive devices for the treatment of prostate diseases
EP2120900A2 (en) 2007-02-15 2009-11-25 Novartis AG Combination of lbh589 with other therapeutic agents for treating cancer
US20080245375A1 (en) * 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
EP2167090A4 (en) 2007-06-06 2010-08-25 Univ Maryland HDAC INHIBITORS AND HORMONE TREATMENT MEDICAMENTS
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US20090076158A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched bicalutamide
AR069039A1 (es) * 2007-10-26 2009-12-23 Univ California Compuestos de diarilhidantoina, composicion farmaceutica, proceso de obtencion del compuesto, utiles para desordenes hiperproliferativos
EP2259742B1 (en) 2008-03-06 2020-01-01 AquaBeam LLC Tissue ablation and cautery with optical energy carried in fluid stream
PT2268612E (pt) 2008-03-24 2014-11-13 Novartis Ag Inibidores de metaloprotease de matriz à base de arilsulfonamidas
PT2260020E (pt) 2008-03-26 2014-10-28 Novartis Ag Inibidores das desacetilases b baseados no hidroxamato
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
WO2010088335A1 (en) 2009-01-29 2010-08-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
US9848904B2 (en) 2009-03-06 2017-12-26 Procept Biorobotics Corporation Tissue resection and treatment with shedding pulses
WO2014127242A2 (en) 2013-02-14 2014-08-21 Procept Biorobotics Corporation Aquablation aquabeam eye surgery methods and apparatus
EP2424853B1 (en) 2009-04-10 2018-09-19 Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (I.R.S.T.) S.R.L. Non-steroidal compounds for androgen receptor modulation, processes for the preparation and uses thereof
ITBO20090235A1 (it) * 2009-04-10 2010-10-11 Consiglio Nazionale Ricerche Composti per il trattamento del tumore alla prostata e procedimenti per la loro sintesi
NZ596488A (en) 2009-06-26 2012-11-30 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
US8450374B2 (en) * 2009-06-29 2013-05-28 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
KR20120089643A (ko) 2009-08-12 2012-08-13 노파르티스 아게 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
IN2012DN01453A (enExample) 2009-08-20 2015-06-05 Novartis Ag
KR20120050492A (ko) 2009-08-26 2012-05-18 노파르티스 아게 테트라-치환된 헤테로아릴 화합물 및 ｍｄｍ2 및/또는 ｍｄｍ4 조절제로서의 그의 용도
BR112012005400A2 (pt) 2009-09-10 2016-04-05 Irm Llc derivados do tipo éter de heteroarilas bicíclicas
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
JP5466767B2 (ja) 2009-11-04 2014-04-09 ノバルティス アーゲー Ｍｅｋ阻害剤として有用なヘテロ環式スルホンアミド誘導体
EP2504339A1 (en) 2009-11-25 2012-10-03 Novartis AG Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
WO2011064663A1 (en) 2009-11-25 2011-06-03 Festuccia, Claudio Combination treatment employing belinostat and bicalutamide
PE20121384A1 (es) 2009-12-08 2012-10-13 Novartis Ag Derivados de sulfonamida heterociclicos
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CN101759597B (zh) * 2009-12-31 2013-09-04 上海康鹏化学有限公司 2-三氟甲基-4-氨基苯腈的制备方法
JP2013516501A (ja) * 2010-01-11 2013-05-13 ジーティーエックス・インコーポレイテッド マイボーム腺機能障害を治療する方法
WO2016004071A1 (en) 2014-06-30 2016-01-07 Procept Biorobotics Corporation Fluid jet tissue resection and cold coagulation (aquablation) methods and apparatus
US20130085161A1 (en) 2010-06-17 2013-04-04 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
CN102947274A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
FI20105806A0 (fi) * 2010-07-15 2010-07-15 Medeia Therapeutics Ltd Uudet aryyliamidijohdannaiset, joilla on antiandrogeenisia ominaisuuksia
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
JP2013544768A (ja) 2010-09-29 2013-12-19 シルパ メディケア リミテッド ビカルタミドの調製方法
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US20130338152A1 (en) 2011-03-08 2013-12-19 Irm Llc Fluorophenyl bicyclic heteroaryl compounds
WO2012143599A1 (en) 2011-04-21 2012-10-26 Orion Corporation Androgen receptor modulating carboxamides
EP2702052B1 (en) 2011-04-28 2017-10-18 Novartis AG 17alpha-hydroxylase/c17,20-lyase inhibitors
JP2014513727A (ja) 2011-05-16 2014-06-05 ジェンザイム・コーポレーション Ｃｘｃｒ４拮抗薬の使用
IN2014DN00123A (enExample) 2011-06-09 2015-05-22 Novartis Ag
WO2012175520A1 (en) 2011-06-20 2012-12-27 Novartis Ag Hydroxy substituted isoquinolinone derivatives
WO2012175487A1 (en) 2011-06-20 2012-12-27 Novartis Ag Cyclohexyl isoquinolinone compounds
CA2840315A1 (en) 2011-06-27 2013-01-03 Novartis Ag Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
WO2013080141A1 (en) 2011-11-29 2013-06-06 Novartis Ag Pyrazolopyrrolidine compounds
DK2785349T4 (da) 2011-11-30 2023-01-09 Astrazeneca Ab Kombinationsbehandling af cancer
JO3398B1 (ar) 2011-12-22 2019-10-20 Novartis Ag مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
US20150148377A1 (en) 2011-12-22 2015-05-28 Novartis Ag Quinoline Derivatives
EP2794588A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
CA2859873A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
JP2015503519A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
KR20140104047A (ko) 2011-12-23 2014-08-27 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
KR20140107575A (ko) 2011-12-23 2014-09-04 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
PL2802563T3 (pl) 2012-01-13 2017-11-30 Aranda Pharma Ltd Nowe pochodne heteroaryloamidowe mające własności antyandrogenne
TW201332953A (zh) 2012-01-13 2013-08-16 Medeia Therapeutics Ltd 具抗雄激素性質新芳醯胺衍生物
WO2013104829A1 (en) 2012-01-13 2013-07-18 Medeia Therapeutics Ltd Novel arylamide derivatives having antiandrogenic properties
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
BR112014021482B1 (pt) 2012-02-29 2021-12-21 Procept Biorobotics Corporation Aparelho de ressecção de próstata
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
WO2013152170A1 (en) 2012-04-04 2013-10-10 Catylix, Inc. Selective androgen receptor modulators
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
US20130310387A1 (en) 2012-05-16 2013-11-21 Novartis Ag Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
WO2013175417A1 (en) 2012-05-24 2013-11-28 Novartis Ag Pyrrolopyrrolidinone compounds
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
CN108143728A (zh) 2012-07-13 2018-06-12 Gtx公司 选择性雄激素受体调节剂在治疗乳癌中的用途
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
JP6236083B2 (ja) 2012-08-13 2017-11-22 ノバルティス ティーアゲズントハイト アーゲー 脾臓チロシンキナーゼ（ｓｙｋ）の阻害剤としての二環式ヘテロアリールシクロアルキルジアミン誘導体
KR102160320B1 (ko) 2012-10-02 2020-09-28 에피테라퓨틱스 에이피에스 히스톤 탈메틸효소의 저해제
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
RU2510392C1 (ru) * 2012-12-21 2014-03-27 Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской академии наук (ИХР РАН) Сокристаллическая форма бикалутамида
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
ES2670864T3 (es) 2013-02-27 2018-06-01 Gilead Sciences, Inc. Inhibidores de histonas desmetilasas
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
EP3041422A4 (en) 2013-09-06 2017-04-12 Procept Biorobotics Corporation Automated image-guided tissue resection and treatment
AU2014321420B2 (en) 2013-09-22 2017-06-15 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN103772238B (zh) * 2014-01-24 2017-03-22 苏州伊莱特新药研发有限公司 一类新的含酯基芳香丙酰胺化合物及其制备方法和用途
US9403801B2 (en) 2014-03-28 2016-08-02 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
TW201625535A (en) 2014-03-31 2016-07-16 Epitherapeutics Aps Inhibitors of histone demethylases
WO2015196144A2 (en) 2014-06-20 2015-12-23 England Pamela M Androgen receptor antagonists
CN104151197B (zh) * 2014-07-25 2017-02-22 苏州伊莱特新药研发有限公司 芳香丙酰胺类化合物及其制备方法和应用
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
EP3174869B1 (en) 2014-07-31 2020-08-19 Novartis AG Combination therapy of a met inhibitor and an egfr inhibitor
TW201625536A (zh) 2014-08-27 2016-07-16 艾比療法公司 抑制組蛋白去甲基酶之化合物及方法
CN107072591B (zh) 2014-09-05 2021-10-26 普罗赛普特生物机器人公司 与靶器官图像的治疗映射结合的医师控制的组织切除
WO2016079521A1 (en) 2014-11-20 2016-05-26 University College Cardiff Consultants Limited Androgen receptor modulators and their use as anti-cancer agents
WO2016079522A1 (en) 2014-11-20 2016-05-26 University College Cardiff Consultants Limited Androgen receptor modulators and their use as anti-cancer agents
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
AU2016252753A1 (en) 2015-04-21 2017-11-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
MX2017013565A (es) 2015-04-21 2018-02-19 Gtx Inc Ligandos degradadores selectivos del receptor androgénico (sard) y sus métodos uso.
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CN106748884B (zh) * 2016-12-13 2021-08-20 山西振东制药股份有限公司 一种比卡鲁胺中间体的制备方法
JP7254076B2 (ja) 2017-11-19 2023-04-07 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換ヘテロアリール化合物及び使用方法
EP3730483B1 (en) 2017-12-21 2023-08-30 Hefei Institutes of Physical Science, Chinese Academy of Sciences Class of pyrimidine derivative kinase inhibitors
KR102737185B1 (ko) 2018-01-20 2024-12-05 선샤인 레이크 파르마 컴퍼니 리미티드 치환된 아미노피리미딘 화합물 및 이의 사용 방법
WO2019222272A1 (en) 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US12202815B2 (en) 2018-09-05 2025-01-21 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
WO2020095183A1 (en) 2018-11-05 2020-05-14 Pfizer Inc. Combination for treating cancer
CN109438297B (zh) * 2018-12-03 2021-05-14 昆明积大制药股份有限公司 雄激素受体拮抗剂、其制备方法及其应用
BR112021020864A2 (pt) 2019-04-19 2021-12-14 Ligand Pharm Inc Formas cristalinas e métodos de produção de formas cristalinas de um composto
CA3138197A1 (en) 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2021183973A1 (en) 2020-03-13 2021-09-16 Research Development Foundation Methods for diagnosing and treating cancers
IL300581A (en) 2020-08-13 2023-04-01 Pfizer Combined treatment
JP2024510666A (ja) 2021-03-24 2024-03-08 ファイザー・インク Ｄｄｒ遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
WO2025045058A1 (zh) * 2023-08-28 2025-03-06 中国药科大学 作为雄激素受体拮抗剂的化合物
WO2025067483A1 (zh) * 2023-09-28 2025-04-03 中国药科大学 酰胺类化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133119A (en) * 1961-11-09 1964-05-12 Givaudan Corp Substituted acetanilides and propionanilides
US3995060A (en) * 1972-06-20 1976-11-30 Schering Corporation Antiandrogenic agents and method for the treatment of androgen dependent disease states
CH493198A (de) * 1968-05-06 1970-07-15 Ciba Geigy Schädlingsbekämpfungsmittel
FR2142803A1 (en) * 1971-06-25 1973-02-02 Scherico Ltd 3,4-disubstd anilides - having antiandrogenic activity
US3875229A (en) * 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
US4144270A (en) * 1973-04-19 1979-03-13 Schering Corporation Substituted anilides as anti-androgens
US4329364A (en) * 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4039684A (en) * 1976-03-25 1977-08-02 Schering Corporation Method for treatment of canine seborrhea
JPS6044294B2 (ja) * 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) * 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
EP0002309B1 (en) * 1977-10-12 1982-12-01 Imperial Chemical Industries Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) * 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) * 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
NO164974C (no) 1990-12-05
GR79232B (enExample) 1984-10-22
JPS5933250A (ja) 1984-02-23
DK322783D0 (da) 1983-07-13
ATE28864T1 (de) 1987-08-15
ES544189A0 (es) 1986-09-16
EP0100172A1 (en) 1984-02-08
ES8607915A1 (es) 1986-06-01
AU1693783A (en) 1984-01-26
JPH0432061B2 (enExample) 1992-05-28
ES8700231A1 (es) 1986-09-16
IE831732L (en) 1984-01-23
ES8601106A1 (es) 1985-11-01
CS399991A3 (en) 1992-06-17
PT77087A (en) 1983-08-01
MX9203451A (es) 1992-08-01
FI83770C (fi) 1991-08-26
IL69217A (en) 1987-03-31
FI832644A7 (fi) 1984-01-24
NZ204995A (en) 1985-08-30
NL950029I2 (nl) 1997-03-03
HK92690A (en) 1990-11-16
NO1996014I1 (no) 1996-12-10
NO164974B (no) 1990-08-27
US4636505A (en) 1987-01-13
IL69217A0 (en) 1983-11-30
ES8607936A1 (es) 1986-06-01
JPH02131462A (ja) 1990-05-21
HU191296B (en) 1987-02-27
IE55941B1 (en) 1991-02-27
ZA835182B (en) 1984-05-30
PT77087B (en) 1986-01-27
LU88769I2 (fr) 1996-11-05
EP0100172B1 (en) 1987-08-12
FI83770B (fi) 1991-05-15
AU556328B2 (en) 1986-10-30
ES539614A0 (es) 1986-06-01
CA1249823A (en) 1989-02-07
NL950029I1 (enExample) 1996-02-01
NO832599L (no) 1984-01-24
ES524392A0 (es) 1985-11-01
FI832644A0 (fi) 1983-07-20
ES539615A0 (es) 1986-06-01

Similar Documents

Publication Publication Date Title
DE3372965D1 (en) Amide derivatives
DE3369315D1 (en) Derivatives of 2-amino-3-acylamino-6-benzylamino pyridine with an anti-epileptic activity
DE3360904D1 (de) A fungicidal indanylbenzamide
DK420682A (da) Fremgangsmaade til fremstilling af triazoloquinazoloner eller salte deraf
ES8701151A1 (es) Un procedimiento para la produccion de derivados de benzoilurea.
PL237069A1 (en) Herbicide and process for manufacturing active substance therefor
AU563453B2 (en) Substituted 4h-3,1-benzoxazin-2-ones
DK11184A (da) Amidderivater
ES466026A1 (es) Procedimiento para la obtencion de ditiocarbamatos de hidro-xialquilo.
DE3276310D1 (en) Arylsulphonyl urea derivatives; their use as herbicides; and herbicidal compositions containing them
IL76155A0 (en) Benzoylurea derivatives,their preparation and pesticidal compositions containing them
ES8106288A1 (es) Un procedimiento para la preparacion de carbamatos de n-(2- isobutironitrilsulfenil)-n-metil-oxima
IL76156A0 (en) Benzoylurea derivatives,their preparation and pesticidal compositions containing them
ZA831122B (en) Substituted oximinoacetanilides,processes for their preparation,and their use as pest-combating agents
ES8403899A1 (es) Un procedimiento para la preparacion de nuevos derivados de benzamida.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ZENECA LTD., LONDON, GB

V448 Application of spc

Free format text: PRODUCT NAME: BICALUTAMID; REGISTRATION NO/DATE: 34057.00.00, 19960320

Spc suppl protection certif: 196 75 012

Filing date: 19960529

V457 Spc granted

Free format text: PRODUCT NAME: BICALUTAMID; REGISTRATION NO/DATE: 34057.00.00, 19960320

Spc suppl protection certif: 196 75 012

Filing date: 19960529

8327 Change in the person/name/address of the patent owner

Owner name: ASTRAZENECA UK LTD., LONDON, GB

V464 Spc expired

Free format text: PRODUCT NAME: BICALUTAMID; REGISTRATION NO/DATE: 34057.00.00, 19960320

Spc suppl protection certif: 196 75 012

Filing date: 19960529